Increasing Prevalence of Chronic Diseases to Augment the Hospital Pharmaceuticals Market Growth

Hospital pharmaceuticals consist of medicines purchased for hospitals, healthcare centers to be administered to patients during hospitalization. Hospital pharmaceuticals include therapeutic and critical care drugs applied in infections, neurology, urology, cardiology, hematology, dermatology, respiratory system, musculoskeletal system, sensory organs, alimentary tract and metabolism, and other. The primary responsibility of hospital pharmacy is procurement, storage and selling of medications.

Market Dynamics:

Increasing incidence or prevalence of chronic diseases across the world, especially in the North America, is expected to propel the growth of the hospital pharmaceuticals market. For instance, chronic diseases such as diabetes, cancer, and heart disease, are the leading causes of death and disability in the United States, according to the Centers for Disease Control and Prevention (CDC). They are also leading drivers of the nation's $3.8 trillion in annual health care costs.

Moreover, the emergence of COVID-19 (SARS-CoV-2) is expected to augment the growth of the hospital pharmaceuticals market. For instance, in February 2021, Facing the challenge of a fast-paced and complex rollout of COVID-19 vaccines, Pennsylvania Hospital deployed radio frequency identification (RFID) technology to track the status of every vial that is removed from an ultra-freezer, then transported to the vaccination clinic, and sometimes returned to refrigeration, all while ensuring no vial expires before reaching a patient's arm.

Increasing demand for hospital pharmaceuticals and increasing spending on pharmaceuticals is also expected to fuel the growth of the hospital pharmaceuticals market. However,

Competitive Analysis:

Major players operating in the hospital pharmaceuticals market are Eli Lilly and Company, Merck & Co., Sanofi S.A., F. Hoffmann-La Roche Ltd, Johnson & Johnson, GlaxoSmithKline Plc., AstraZeneca Plc., Pfizer, Inc., Novartis AG, and Bayer AG.

Major players in the market are adopting various strategies, such as partnership, collaboration, product launch, etc., to enhance their market presence. For instance, in February 2021, Recce Pharma Ltd. formalized an agreement with Fiona Stanley Hospital for a Phase 1/2 clinical trial to assess the potential of RECCE 327’s new spray-on, broad-spectrum antibiotic for the treatment of topical burn wound infections.

In February 2021, Algernon Pharmaceuticals provided an update on the final data set of the Phase 2b part of the Phase 2b/3 COVID-19 Ifenprodil study.

In February 2021, Valeo Pharma and Ingenew Pharma announced that HespercoTM capsules, approved by Health Canada for immune support, will be at the core of the Montreal Heart Institute's clinical trial, "The Hesperidin Coronavirus Study".

Comments

Fc Protein and Glycoengineered Antibodies Market Is Booming Worldwide 2023-2028

Global Fc Protein and Glycoengineered Antibodies Market Drivers Key players in the market are focusing on research and development activities and receiving approvals from regulatory bodies, which are expected to boost the global Fc protein and glycoengineered antibodies market growth over the forecast period. For instance, in 2016, Genentech Inc. received approval from the U.S. Food and drug Administration (U.S. FDA) for Tecentriq (Atezolizumab). It is being used for the treatment of urothelial carcinoma. In March 2019, Tecentriq received its second approval from the U.S. FDA for the treatment of small lung cancer. Furthermore, in November 2017, TG Therapeutics, Inc. began its clinical trial of Ublituximab for the treatment of multiple sclerosis. It is currently in third phase of its clinical trial. Factors such as increasing product approvals and robust pipeline are expected to drive the global fc protein and glycoengineered antibodies market growth. Increasing preva...

Breathalyzers Market Development Analysis Contributing Top Vendor Landscape and Economic Growth 2028

The breathalyzer market refers to the sales and distribution of devices used for measuring blood alcohol content (BAC) through analysis of a breath sample. These devices are widely used by law enforcement agencies for detecting drunk drivers and in workplaces for alcohol screening. The market has been growing due to increasing awareness about the dangers of drunk driving, stricter laws and penalties, and advancements in technology that have made breathalyzers more portable and user-friendly. The market is expected to continue growing in the future as demand for personal and professional use breathalyzers increases. Breathalyzers are instruments used for testing blood alcohol levels through an individual’s breath. These devices find application in probation departments, police departments, remand homes, and commercial sector. The global breathalyzers market is estimated to account for US$ 6,384.5 Mn in terms of value in 2020 and is expected to reach US$ 71,8...

Increasing Incidences of Infectious Diseases to Augment the Antibacterial Drugs Market Growth

Antibacterial drugs are widely used to treat and prevent infectious diseases and are categorized into seven major classes, such as β-Lactams, phenicols, macrolides, quinolones, sulfonamides, tetracyclines, and aminoglycosides, based on their molecular structure. Antibacterial drugs destroy or slow down the growth of bacteria. These medications are also used to treat urinary infections caused by S. aureus, E. coli, Streptococcus pyogenes, and other bacterial infections. They include a range of powerful drugs used to treat diseases caused by bacteria. Antibiotics cannot treat viral infections, such as cold, flu, and most coughs. Antibacterial drugs play a major role in advanced healthcare, as they are widely used to treat infectious diseases, such as tuberculosis, malaria, typhoid, leprosy, hepatitis B, HIV/AIDS, and others. Thus, there is an increasing demand for antibacterial drugs worldwide.

Healthcare News

Search This Blog